PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: General Electric Company

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

GE Healthcare Expands Cell Therapy Portfolio with License of STEMCELL Technologies’ T-Cell Reagents - Exclusive licensing agreement will provide cGMP grade reagents to further enable development and manufacturing of cellular immunotherapies - STEMCELL.com / GEHealthcare.com
GE Healthcare Expands Cell Therapy Portfolio with License of STEMCELL Technologies’ T-Cell Reagents

 

NewswireToday - /newswire/ - Chalfont St Giles, United Kingdom, 2016/08/23 - Exclusive licensing agreement will provide cGMP grade reagents to further enable development and manufacturing of cellular immunotherapies - STEMCELL.com / GEHealthcare.com. NYSE: GE

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services/Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

In a further step to build its portfolio for the rapidly-growing cell therapy industry, GE Healthcare today announced an agreement with STEMCELL Technologies, Inc. of Vancouver, Canada to provide T-Cell reagents for commercial-scale cell therapy production. Under the agreement, GE Healthcare will commercialize cGMP-grade versions of STEMCELL Technologies’ T-Cell reagents for the isolation, activation, and culture of T-cells in clinical applications. These reagents are critical tools in the development and manufacturing of cell and gene therapies intended for administration to patients.

Cindy Collins, GM Cell Therapy, GE Healthcare, said: “As cell therapies move to commercialization, the need increases for technologies and industrial capabilities that enable efficient, scalable production of these therapies. The availability of cGMP grade T-Cell reagents significantly expands the complete solution that our customers need to bring cell therapies into widespread clinical practice.”

Allen Eaves, President and CEO of STEMCELL Technologies Inc. said: “This partnership with GE will give our customers the confidence of a path to the clinic with a suite of critical cGMP grade T-cell reagents. STEMCELL is a recognized leader in cell culture media and cell separation products and GE can leverage our expertise in T-cell isolation, activation and culture to help the industry evolve and make these promising therapies, such as CAR-T cells and TCR-engineered T cells, a clinical reality.”

The exclusive licensing agreement supports GE’s mission to provide an ecosystem of tools and services to the cell therapy industry, and builds on the recent acquisition of Biosafe Group, which added integrated cell bioprocessing systems to GE’s portfolio of manufacturing tools and technologies.

In 2016, GE has made other significant investments in the rapidly growing cell therapy and regenerative medicine industry, including a US $31.5 million co-investment with the Canadian government to create BridGE@CCRM for the acceleration of cellular technologies. In April, GE Ventures and Mayo Clinic announced they would bring capacity and digital infrastructure to the industry with Vitruvian Networks, Inc., an independent platform company accelerating access to cell and gene therapies through advanced, cloud-ready software systems and manufacturing services.

The following proprietary reagents from STEMCELL Technologies will be qualified as cGMP-grade materials and licensed by GE Healthcare:

• ImmunoCultTM Human CD3/CD28 T-Cell Activator;
• ImmunoCultTM Human CD3/CD28/CD2 T-Cell Activator;
• EasySep™ Release Human CD3 Positive Selection Kit;
• ImmunoCultTM XF T-Cell Expansion Medium.

About GE Healthcare
GE Healthcare (gehealthcare.com) provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE works on things that matter - great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients.

About STEMCELL Technologies, Inc.
As Scientists Helping Scientists, STEMCELL Technologies, Inc. (stemcell.com) is committed to providing high-quality cell culture media, cell isolation products and accessory reagents for life science research. Driven by science and a passion for quality, STEMCELL Technologies provides over 2000 products to more than 70 countries worldwide. STEMCELL Technologies’ specialty cell culture reagents, instruments and tools are designed to support science along the basic to translational research continuum.

Contact: Andrew Booth - STEMCELL Technologies
P: 604-675-7819 - E: andrew.booth[.]stemcell.com.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services/Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: General Electric Company

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Medical Services/Equipment articles,
CATCH Visitors via Your Competitors Announcements!


GE Healthcare Expands Cell Therapy Portfolio with License of STEMCELL Technologies’ T-Cell Reagents

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

GE Healthcare | STEMCELL Technologies Inc
Publisher Contact: Erin Bryant - GE Healthcare 
203-450-5326 erin.bryant[.]ge.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any General Electric Company securities in any jurisdiction including any other companies listed or named in this release.

Medical Services/Equipment via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From General Electric Company / Company Profile


Read Medical Services/Equipment Most Recent Related Newswires:

Neuronix Ltd Announces the First Group of Mild to Moderate Alzheimer Patients to be Successfully Treated by The NeuroAD™ Therapy System
SelectMDx to be Distributed Across Middle East by IPS Genomix
GE Healthcare Partners with Oritain to Introduce Independent Test to Confirm Country of Origin of Fetal Bovine Serum
Saebo, Inc. Awarded Patent for Low-Profile Stroke Recovery Glove
GE Healthcare and HeartFlow Announce Global Cardiovascular Collaboration
Insulin Delivery Devices Market Size to Expand at 7% CAGR through 2020 Says PMR
Intubation Market Significant Profits Estimated to be Generated by 2025 Says Persistence Market Research
PMR Releases Report for Next Generation IV Infusion Pumps Market Impact of Existing and Emerging Market 2017-2025
Medical Tapes Market to Reach US$ 2Bn by 2024 Reports PMR
Global Pyrogen Testing Market Value Expected to Increase to US$ 1.37 Billion by 2024 Says PMR
Huber Needles Market Expected to Reach US$ 55M by 2024 According to PMR
ZOLL Technologies for Improving CPR Quality to be Showcased at NTI 2017
ConfirmMDx Improves Prostate Cancer Diagnosis in African American Men
Biomarker-based Technologies to Disrupt Conventional Diagnosis in Diabetes Management across the Globe Finds Frost & Sullivan
Agfa Specialty Products Announces the Launch of UNIQOAT

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Rapid Recovery

Visit  NAKIVO, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)